Clinical Trial: Oleclumab (MEDI9447) EGFRm NSCLC Novel Combination Study

U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT03381274) titled 'Oleclumab (MEDI9447) EGFRm NSCLC Novel Combination Study' on Dec. 18, 2017.

Brief Summary: The objective of this study is to investigate the safety, tolerability and antitumor activity of novel combination therapies administered in subjects with advanced EGFRm NSCLC

Study Type: Interventional

Condition: Carcinoma, Non-Small-Cell Lung

Intervention: * Biological: MEDI9447

Subjects will receive MEDI9447 in combination with osimertinib or AZD4635 until disease progression

* Drug: Osimertinib

Subjects will receive osimertinib in combination with MEDI9447 until disease progression

* Drug: AZD4635

Subjects will receive AZD4635 in c...